

## GENERAL INFORMATION

**Chair:** Arne C. Rodloff

### Organising Committee

Ian Gould  
Fiona MacKenzie  
Kurt G. Naber  
Jean Claude Pechere  
Bernhard Ruf  
Pramod Shah  
Glenn Tillotson

### Contact Details

Prof. Arne C. Rodloff, MD  
Inst. Med. Microbiology & Infection Epidemiology,  
University of Leipzig  
Liebigstr. 24, D-04103 Leipzig, Germany  
Tel.: +49-341-9715 20, Fax: +49-341-9715 209  
acr@medizin.uni-leipzig.de

Prof. Kurt G. Naber, MD  
President of the International Society of  
Chemotherapy (ISC)  
Karl-Bickleder-Str. 44 C, D-94315 Straubing, Germany  
Tel.: +49-9421-33369, kurt@nabers.de

Dr. Fiona M. MacKenzie  
ISC Office  
Medical Microbiology Aberdeen Royal  
Infirmary Foresterhill  
Aberdeen AB25 2ZN, UK  
Tel.: +44-1224-552127, Fax: +44-1224-550632  
isc@abdn.ac.uk

### Organisation (PCO)



KelCon GmbH  
Dana Schlameuß  
Ludwigstraße 24-26  
D-63110 Rodgau - Jügesheim, Germany  
Tel.: +49-6106-84 44 16, Fax: +49-6106-84 44 44  
d.schlameuss@kelcon.de

## VENUE

Renaissance Hotel Leipzig  
Großer Brockhaus 3  
D-04103 Leipzig, Germany  
Tel.: +49-341-12 92 113  
Fax: +49-341-12 92 125

## SPONSORS

Acambis	Genzyme Virotech
Bayer HealthCare	Merck & Co.
BD Diagnostics	Oxoid
bioMérieux	ViroPharma
Cepheid Europe	Wyeth Pharma

## COOPERATING SOCIETIES

Deutsche Akademie der Naturforscher Leopoldina  
Deutsche Gesellschaft für Hygiene und  
Mikrobiologie (DGHM)  
Deutsche Gesellschaft für Infektiologie (DGI)  
Deutsche Gesellschaft für Verdauungs- und  
Stoffwechselkrankheiten (DGVS)  
Federation of European Societies for  
Chemotherapy and Infection (FESCI)  
Infekt-Liga  
Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)  
Robert-Koch-Institut (RKI)

The ISC International Conference is also supported  
by the Deutsche Forschungsgemeinschaft.

### Certification

The congress is certified with 15 points of the category  
A by the State Chamber of Physicians of Saxony.

## ISC International Conference

## NEW VIEWS ON CLOSTRIDIUM DIFFICILE INFECTIONS



Renaissance Hotel  
Leipzig, Germany  
September 26 - 27, 2008

# PROGRAMME

## Friday, September 26, 2008

### 12:00 - 13:00 Welcome Buffet

13:00 - 13:10 Welcome Address  
(A. C. Rodloff, K.G. Naber, Germany)

13:10 - 13:40 Keynote lecture: *C difficile* 30 years on: what has changed and why?  
(D. Gerding, USA)

### 13:40 - 15:30 Epidemiology

(Chair: M. Delmée, Belgium; E. Jacobs, Germany)

13:40 - 14:00 North American perspective (B.M. Limbago, USA)

14:00 - 14:20 European/RoW perspectives  
(E. Kuijper, The Netherlands)

14:20 - 14:30 Discussion

14:30 - 14:50 Genotypic & phenotypic variants of *C difficile* (M. Rupnik, Slovenia)

14:50 - 15:10 Clinical impact of *C difficile* (E. Bouza, Spain)

15:10 - 15:20 Invited oral presentations  
Characterization of *C difficile* isolates by using *slpA* and *tcdC* gene sequencing  
(L. von Müller, Germany)

15:20 - 15:30 Discussion

15:30 - 16:00 Coffee break

### 16:00 - 18:30 Pathogenesis & diagnosis

(Chair: E. Kuijper, The Netherlands; I. Gould, UK)

16:00 - 16:20 Normal flora; what needs to change to cause CDI (T. Louie, Canada)

16:20 - 16:40 Changing perspectives of *C difficile* virulence and pathogenesis  
(A. Collignon, France)

16:40 - 16:50 Invited oral presentations  
Toxigenic status and Antibiotic susceptibility of *C difficile* strains in Hungary  
(G. Terhes, Hungary)

16:50 - 17:00 Discussion

# PROGRAMME

17:00 - 17:20 Laboratory diagnosis of *C difficile* - associated diarrhoea: a plea for culture  
(M. Delmée, Belgium)

17:20 - 17:40 What is the role of antimicrobial resistance in the new epidemic of *C difficile*?  
(J. Coia, UK)

17:40 - 18:00 Have fluoroquinolones selected the hyper-virulent strain of *C difficile*?  
(K. Weiss, Canada)

18:00 - 18:30 Round table discussion

## Saturday, September 27, 2008

### 08:30 - 11:00 Therapy

(Chair: P. Shah, A.C. Rodloff, Germany)

08:30 - 08:50 New approaches to the management of CDI (D. Gerding, USA)

08:50 - 09:10 Toxin binding approaches (K. Weiss, Canada)

09:10 - 09:20 Invited oral presentations  
In Vito Antimicrobial Activities Of *Garcinia kola* on *C difficile* (T. Egwuatu, Nigeria)

09:20 - 09:40 Discussion

09:40 - 10:00 Vaccination approaches for managing CDI  
(P. Giannasca, USA)

10:00 - 10:20 Anti-inflammatory management of CDI  
(Th. Gruenewald, Germany)

10:20 - 10:40 Alternative strategies for CDI  
(J.T. van Dissel, The Netherlands)

10:40 - 11:00 Discussion

11:00 - 11:30 Coffee break

### 11:30 - 12:40 CDI management - the bigger picture I

(Chair: B. Ruf, G. Stein, Germany)

11:30 - 11:50 Antimicrobial therapy, do all broad spectrum agents select for *C difficile*  
(M. Wilcox, UK)

# PROGRAMME

11:50 - 12:10 Recurrent CDI - causality and therapeutic approaches  
(S. Johnson, USA)

12:10 - 12:20 Invited oral presentations  
Effective disinfection procedures for instruments and surfaces against spores of *C difficile* ribotype 027 (St. Büttgen, Germany)

12:20 - 12:40 Discussion

12:40 - 13:50 Lunch break

### 13:50 - 16:30 CDI management - the bigger picture II

(Chair: R. Burger, H.-J. Epple, Germany)

13:50 - 14:10 Clinical trial design in an era of epidemic CDI (G. Tillotson, USA)

14:10 - 14:30 Surveillance according to CDAD KISS  
(P. Gastmeier, Germany)

14:30 - 14:50 Infection control and CDI (M. Mielke, Germany)

14:50 - 15:00 Discussion

15:00 - 15:20 *C difficile* is no longer just a nosocomial or an adult infection (H. Pituch, Poland)

15:20 - 15:40 Nosocomial Diarrhoea - other agents (G. Gorkiewicz, Austria)

15:40 - 15:50 Invited Oral presentations  
TcdCsubtypes in clinical isolates of *C difficile* at Heidelberg University Hospital (M. Benz, Germany)

15:50 - 16:00 Invited Oral presentations  
WEBRIBO – an internet database for characterization of *C difficile* isolates by capillary gel electrophoresis based PCR ribotyping (A. Indra, Austria)

16:00 - 16:10 Invited Oral Presentations  
NHAS mandatory surveillance programme (A. Pearson, UK)

16:10 - 16:20 Discussion

16:20 - 16:30 Closing remarks

16:30 - 18:00 Research Forum